Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinorelbine + cyclophosphamide + interferon alpha 2b
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous, Intramuscular
01
Overview
This is a combination regimen consisting of three agents—vinorelbine, cyclophosphamide, and interferon alpha 2b—used primarily in investigational settings for the treatment of advanced neoplasms. Vinorelbine is a semi-synthetic vinca alkaloid that inhibits mitosis by binding to tubulin and disrupting microtubule formation in dividing cells. Cyclophosphamide is an alkylating agent that crosslinks DNA strands, leading to cell death. Interferon alpha 2b is a recombinant cytokine with immunomodulatory, antiproliferative, and antiangiogenic properties. The combination has been studied as "metronomic chemotherapy," where low continuous doses are administered to exert antiangiogenic effects while minimizing toxicity[1][2][8]. This regimen aims to target both tumor cells directly (cytotoxicity) and the tumor microenvironment (antiangiogenesis/immunomodulation).
- Brand names
- NavelbineEndoxanIntrona
- Other names
- vinorelbine and cyclophosphamide and interferon alfa-2bmetronomic chemotherapy with vinorelbine, cyclophosphamide, and interferon alpha 2b
02
Targets
DNAIFNAR (Immune system modulation via type I interferon receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vinorelbine + cyclophosphamide + interferon alpha 2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinorelbine + cyclophosphamide + interferon alpha 2b.